Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Nigrovic is active.

Publication


Featured researches published by Peter Nigrovic.


Science | 2010

Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production

Eric Boilard; Peter Nigrovic; Katherine Larabee; Gerald F. Watts; Jonathan S. Coblyn; Michael E. Weinblatt; Elena Massarotti; Eileen Remold-O'Donnell; Richard W. Farndale; Jerry Ware; David M. Lee

Platelet Microparticles Drive Inflammatory Arthritis Platelets are best known for their critical role in blood clot formation during wound repair, but an appreciation for their role in inflammatory processes is growing. Platelet-derived cellular microparticles (MPs) are small membrane vesicles released from platelets in response to cell activation that can transport biomolecules throughout the body that have also been implicated in inflammatory processes. Boilard et al. (p. 580; see the Perspective by Zimmerman and Weyrich) have now found that platelet-derived MPs probably contribute to the inflammatory processes underlying rheumatoid arthritis, an autoimmune disease. The majority of MPs in synovial fluid from patients with various types of inflammatory arthritis were platelet-derived and, importantly, platelet-derived MPs were lacking in synovial fluid from osteoarthritis patients. Furthermore, platelet depletion abrogated disease development in a mouse model of inflammatory arthritis. Microparticles released by platelets contribute to inflammation underlying rheumatoid arthritis. In addition to their pivotal role in thrombosis and wound repair, platelets participate in inflammatory responses. We investigated the role of platelets in the autoimmune disease rheumatoid arthritis. We identified platelet microparticles—submicrometer vesicles elaborated by activated platelets—in joint fluid from patients with rheumatoid arthritis and other forms of inflammatory arthritis, but not in joint fluid from patients with osteoarthritis. Platelet microparticles were proinflammatory, eliciting cytokine responses from synovial fibroblasts via interleukin-1. Consistent with these findings, depletion of platelets attenuated murine inflammatory arthritis. Using both pharmacologic and genetic approaches, we identified the collagen receptor glycoprotein VI as a key trigger for platelet microparticle generation in arthritis pathophysiology. Thus, these findings demonstrate a previously unappreciated role for platelets and their activation-induced microparticles in inflammatory joint diseases.


Arthritis & Rheumatism | 2011

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

Peter Nigrovic; Melissa L. Mannion; Femke H. M. Prince; Andrew Zeft; C. Egla Rabinovich; Marion A. J. van Rossum; Elisabetta Cortis; Manuela Pardeo; Paivi Miettunen; Ginger Janow; James D. Birmingham; Aaron T Eggebeen; Erin Janssen; Andrew I. Shulman; Mary Beth Son; Sandy D. Hong; Karla N. Jones; Norman T. Ilowite; Randy Q. Cron; Gloria C. Higgins

OBJECTIVE To examine the safety and efficacy of the interleukin-1 (IL-1) receptor antagonist anakinra as first-line therapy for systemic juvenile idiopathic arthritis (JIA). METHODS Patients with systemic JIA receiving anakinra as part of initial disease-modifying antirheumatic drug (DMARD) therapy were identified from 11 centers in 4 countries. Medical records were abstracted using a standardized instrument, and resulting data were analyzed to characterize concomitant therapies, clinical course, adverse events, and predictors of outcome. RESULTS Among 46 patients meeting inclusion criteria, anakinra monotherapy was used in 10 patients (22%), while 67% received corticosteroids and 33% received additional DMARDs. Outcomes were evaluated at a median followup interval of 14.5 months. Fever and rash resolved within 1 month in >95% of patients, while C-reactive protein and ferritin normalized within this interval in >80% of patients. Active arthritis persisted at 1 month in 39% of patients, at 3 months in 27%, and at >6 months of followup in 11%. Approximately 60% of patients, including 8 of 10 receiving anakinra monotherapy, attained a complete response without escalation of therapy. Disease characteristics and treatment were similar in partial and complete responders, except that partial responders were markedly younger at onset (median age 5.2 years versus 10.2 years; P = 0.004). Associated adverse events included documented bacterial infection in 2 patients and hepatitis in 1 patient. Tachyphylaxis was not observed. CONCLUSION Anakinra as first-line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined. These results justify further study of IL-1 inhibition as first-line, rather than rescue, therapy in systemic JIA.


Nature Genetics | 2013

Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis

Anne Hinks; Joanna Cobb; Miranda C. Marion; Sampath Prahalad; Marc Sudman; John Bowes; Paul Martin; Mary E. Comeau; Satria Sajuthi; Robert K Andrews; Milton R. Brown; Wei-Min Chen; Patrick Concannon; Panos Deloukas; Sarah Edkins; Stephen Eyre; Patrick M. Gaffney; Stephen L. Guthery; Joel M. Guthridge; Sarah Hunt; Judith A. James; Mehdi Keddache; Kathy L. Moser; Peter Nigrovic; Suna Onengut-Gumuscu; Mitchell L. Onslow; Carlos D. Rose; Stephen S. Rich; Kathryn Steel; Edward K. Wakeland

We used the Immunochip array to analyze 2,816 individuals with juvenile idiopathic arthritis (JIA), comprising the most common subtypes (oligoarticular and rheumatoid factor–negative polyarticular JIA), and 13,056 controls. We confirmed association of 3 known JIA risk loci (the human leukocyte antigen (HLA) region, PTPN22 and PTPN2) and identified 14 loci reaching genome-wide significance (P < 5 × 10−8) for the first time. Eleven additional new regions showed suggestive evidence of association with JIA (P < 1 × 10−6). Dense mapping of loci along with bioinformatics analysis refined the associations to one gene in each of eight regions, highlighting crucial pathways, including the interleukin (IL)-2 pathway, in JIA disease pathogenesis. The entire Immunochip content, the HLA region and the top 27 loci (P < 1 × 10−6) explain an estimated 18, 13 and 6% of the risk of JIA, respectively. In summary, this is the largest collection of JIA cases investigated so far and provides new insight into the genetic basis of this childhood autoimmune disease.


Journal of Clinical Investigation | 2013

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

Margaret E. Ackerman; Matthew Crispin; Xiaojie Yu; Kavitha Baruah; Austin W. Boesch; David J. Harvey; Anne Sophie Dugast; Erin L. Heizen; Altan Ercan; Ickwon Choi; Hendrik Streeck; Peter Nigrovic; Chris Bailey-Kellogg; Chris Scanlan; Galit Alter

While the induction of a neutralizing antibody response against HIV remains a daunting goal, data from both natural infection and vaccine-induced immune responses suggest that it may be possible to induce antibodies with enhanced Fc effector activity and improved antiviral control via vaccination. However, the specific features of naturally induced HIV-specific antibodies that allow for the potent recruitment of antiviral activity and the means by which these functions are regulated are poorly defined. Because antibody effector functions are critically dependent on antibody Fc domain glycosylation, we aimed to define the natural glycoforms associated with robust Fc-mediated antiviral activity. We demonstrate that spontaneous control of HIV and improved antiviral activity are associated with a dramatic shift in the global antibody-glycosylation profile toward agalactosylated glycoforms. HIV-specific antibodies exhibited an even greater frequency of agalactosylated, afucosylated, and asialylated glycans. These glycoforms were associated with enhanced Fc-mediated reduction of viral replication and enhanced Fc receptor binding and were consistent with transcriptional profiling of glycosyltransferases in peripheral B cells. These data suggest that B cell programs tune antibody glycosylation actively in an antigen-specific manner, potentially contributing to antiviral control during HIV infection.


Arthritis & Rheumatism | 2013

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications

Sarah Ringold; Pamela F. Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T. Ilowite; Yukiko Kimura; Ronald M. Laxer; Daniel J. Lovell; Peter Nigrovic; Angela Byun Robinson; Richard K. Vehe

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patients individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service.


Proceedings of the National Academy of Sciences of the United States of America | 2007

Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1

Peter Nigrovic; Bryce A. Binstadt; Paul A. Monach; Alyssa Johnsen; Michael F. Gurish; Yoichiro Iwakura; Christophe Benoist; Diane Mathis; David M. Lee

Mast cells are immune sentinels that participate in the defense against bacteria and parasites. Resident within the joint, mast cells become activated in human rheumatoid arthritis and are implicated in the pathogenesis of experimental murine synovitis. However, their arthritogenic role remains undefined. Using a model of autoantibody-induced arthritis, we show that mast cells contribute to the initiation of inflammation within the joint by elaboration of IL-1. Mast cells become activated to produce this cytokine via the IgG immune complex receptor FcγRIII. Interestingly, mast cells become dispensable for the perpetuation of arthritis after delivery of IL-1, highlighting the contribution of this lineage to arthritis induction. These findings illuminate a mechanism by which mast cells can participate in the pathogenesis of autoimmune inflammatory arthritis and provide insights of potential relevance to human rheumatoid arthritis.


Blood | 2014

Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation

Luc H. Boudreau; Anne Claire Duchez; Nathalie Cloutier; Denis Soulet; Nicolas Martin; James G. Bollinger; Alexandre Paré; Matthieu Rousseau; Gajendra S. Naika; Tania Lévesque; Cynthia Laflamme; Geneviève Marcoux; Gérard Lambeau; Richard W. Farndale; Marc Pouliot; Hind Hamzeh-Cognasse; Fabrice Cognasse; Olivier Garraud; Peter Nigrovic; Helga Guderley; Steve Lacroix; Louis Thibault; John W. Semple; Michael H. Gelb; Eric Boilard

Mitochondrial DNA (mtDNA) is a highly potent inflammatory trigger and is reportedly found outside the cells in blood in various pathologies. Platelets are abundant in blood where they promote hemostasis. Although lacking a nucleus, platelets contain functional mitochondria. On activation, platelets produce extracellular vesicles known as microparticles. We hypothesized that activated platelets could also release their mitochondria. We show that activated platelets release respiratory-competent mitochondria, both within membrane-encapsulated microparticles and as free organelles. Extracellular mitochondria are found in platelet concentrates used for transfusion and are present at higher levels in those that induced acute reactions (febrile nonhemolytic reactions, skin manifestations, and cardiovascular events) in transfused patients. We establish that the mitochondrion is an endogenous substrate of secreted phospholipase A2 IIA (sPLA2-IIA), a phospholipase otherwise specific for bacteria, likely reflecting the ancestral proteobacteria origin of mitochondria. The hydrolysis of the mitochondrial membrane by sPLA2-IIA yields inflammatory mediators (ie, lysophospholipids, fatty acids, and mtDNA) that promote leukocyte activation. Two-photon microscopy in live transfused animals revealed that extracellular mitochondria interact with neutrophils in vivo, triggering neutrophil adhesion to the endothelial wall. Our findings identify extracellular mitochondria, produced by platelets, at the midpoint of a potent mechanism leading to inflammatory responses.


Journal of Immunology | 2009

Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes.

Kichul Shin; Peter Nigrovic; James F. Crish; Eric Boilard; H. Patrick McNeil; Katherine Larabee; Roberto Adachi; Michael F. Gurish; Reuben Gobezie; Richard L. Stevens; David M. Lee

Although mast cells (MCs) often are abundant in the synovial tissues of patients with rheumatoid arthritis, the contribution of MCs to joint inflammation and cartilage loss remains poorly understood. MC-restricted tryptase/heparin complexes have proinflammatory activity, and significant amounts of human tryptase β (hTryptase-β) are present in rheumatoid arthritis synovial fluid. Mouse MC protease-6 (mMCP-6) is the ortholog of hTryptase-β, and this serine protease is abundant in the synovium of arthritic mice. We now report that C57BL/6 (B6) mice lacking their tryptase/heparin complexes have attenuated arthritic responses, with mMCP-6 as the dominant tryptase responsible for augmenting neutrophil infiltration in the K/BxN mouse serum-transfer arthritis model. While inflammation in this experimental arthritis model was not dependent on protease-activated receptor-2, it was dependent on the chemokine receptor CXCR2. In support of the latter data, exposure of synovial fibroblasts to hTryptase-β/heparin or mMCP-6/heparin complexes resulted in expression of the neutrophil chemotactic factors CXCL1/KC, CXCL5/LIX, and CXCL8/IL-8. Our proteomics, histochemistry, and immunohistochemistry data also revealed substantial loss of cartilage-derived aggrecan proteoglycans in the arthritic joints of wild-type B6 mice but not mMCP-6-null B6 mice. These observations demonstrate the functional contribution of MC-restricted tryptase/heparin complexes in the K/BxN mouse arthritis model and connect our mouse findings with rheumatoid arthritis pathophysiology.


Immunological Reviews | 2007

Synovial mast cells: role in acute and chronic arthritis

Peter Nigrovic; David M. Lee

Summary:  Mast cells reside in the normal synovium and increase strikingly in number in rheumatoid arthritis and other joint diseases. Given the broad spectrum of activity of this lineage, it has for decades been considered probable that mast cells are involved in the pathophysiology of synovitis. Recent work in murine arthritis has substantiated this suspicion, showing that mast cells can contribute importantly to the initiation of inflammatory arthritis. However, the role of the greatly expanded population of synovial mast cells in established arthritis remains unknown. Here we review the current understanding of mast cell function in acute arthritis and consider the potentially important influence of this cell on key processes within the chronically inflamed synovium, including leukocyte recruitment and activation, fibroblast proliferation, angiogenesis, matrix remodeling, and injury to collagen and bone. We also consider recent evidence supporting an immunomodulatory or anti‐inflammatory role for mast cells as well as pharmacologic approaches to the mast cell as a therapeutic target in inflammatory arthritis.


Arthritis Care and Research | 2012

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.

Esi Morgan DeWitt; Yukiko Kimura; Timothy Beukelman; Peter Nigrovic; Karen Onel; Sampath Prahalad; Rayfel Schneider; Matthew L. Stoll; Sheila T. Angeles-Han; Diana Milojevic; Kenneth N. Schikler; Richard K. Vehe; Jennifer E. Weiss; Pamela F. Weiss; Norman T. Ilowite; Carol A. Wallace

There is wide variation in therapeutic approaches to systemic juvenile idiopathic arthritis (JIA) among North American rheumatologists. Understanding the comparative effectiveness of the diverse therapeutic options available for treatment of systemic JIA can result in better health outcomes. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans and standardized assessment schedules for use in clinical practice to facilitate such studies.

Collaboration


Dive into the Peter Nigrovic's collaboration.

Top Co-Authors

Avatar

Tom W J Huizinga

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert P. Sundel

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yukiko Kimura

Hackensack University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert C. Fuhlbrigge

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Timothy Beukelman

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Matthew L. Stoll

University of Alabama at Birmingham

View shared research outputs
Researchain Logo
Decentralizing Knowledge